Atea Pharmaceuticals Inc (AVIR) showcases strong clinical progress and financial stability while navigating competitive challenges in the HCV treatment landscape.

Advanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected ...

Management outlined ongoing R&D investment and milestone-based payments on licensing agreements as financial commitments.

Management reiterated guidance that patient enrollment for the C-BEYOND trial will complete next month with top line results anticipated in mid-2026. Enrollment for C-FORWARD is expected to finish mid ...

Cash and Investments -- $301.8 million as of December 31, 2025, sufficient to fully fund current Phase III HCV and new HEV programs through 2027. Phase III HCV Trials -- C BEYOND enrollment completed ...

Among rural people with chronic HCV infection and a history of injection drug use, a mobile telemedicine-based intervention vs enhanced usual care improves treatment initiation and cure rates.

A case of a 45-year-old construction worker with a history of intravenous drug use, homelessness, and occasional alcohol and tobacco use.

Poster of distinction at the Liver Meeting covered resistance analyses showing Phase II SVR12 efficacy was not impacted by NS5A resistant variants at baseline. Management noted that most HCV viral ...